Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017
Managing Risk After Intracerebral Hemorrhage in Concomitant Atrial Fibrillation and Cerebral Amyloid Angiopathy
Stroke 47:e190-e192, Stoker, T.B.,et al, 2016
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Bleeding During Treatment with Aspirin Versus Apixaban in Patients with Atrial Fibrillation Unsuitable for Warfarin
Stroke 43:3291-3297, Flaker, G.,et al, 2012
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
NEJM 364:2187-98, 2256, Smith, C.R.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage
Stroke 42:3661-3662, 3665, Steiner, T., 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracereral Hemorrhage
Stroke 42:3663-3664, 3665, Schulman, S., 2011
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Stroke 39:1482-1486,1406, Healey,J.S.,et al, 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Warfarin Versus Aspirin for Stroke Prevention in an Elderly Community Population With Atrial Fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A Randomised Controlled Trial
Lancet 370:493-503,460, Mant,J.,et al, 2007
A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community
JAMA 290:1049-1056,1093, Wang,T.J.,et al, 2003
Stroke Prevention in Atrial Fibrillation
JAMA 290:1093-1095, Waldo,A.L., 2003
Warfarin Therapy for an Octogenarian who has Atrial Fibrillation
Ann Int Med 134:465-474, Gage,B.F.,et al, 2001
Low Molecular-Weight Heparin Versus Aspirin in Patients With Acute Ischaemic Stroke and Atrial Fibrillation: A Double-Blind Randomised Study
Lancet 355:1205-1210, Berge,E.,et al, 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Medical Complications Associated with Carotid Endarterectomy
Stroke 30:1759-1763, Paciaroni,M.,et al, 1999
Heparin in Acute Stroke with Atrial Fibrillation, Clinical Relevance of Very Early Treatment
Arch Neurol 56:1098-1102,1059, Chamorro,A.,et al, 1999
Antithrombotic Therapy to Prevent Stroke in Patients with Atrial Fibrillation:A Meta-Analysis
Ann Int Med 131:492-501,537, Hart,R.G.,et al, 1999